Theresa Frimel
Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1992133086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 274 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,157 and has fallen 77.2% since, to $491 in 2024.
Across 274 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$715
- Abbott$669
- Lilly USA, LLC$478
- AbbVie$477
- Pfizer$357
- Dexcom, Inc.$218
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 34 | $715 |
| Abbott | 40 | $669 |
| Lilly USA, LLC | 38 | $478 |
| AbbVie | 25 | $477 |
| Pfizer | 25 | $357 |
| Dexcom, Inc. | 14 | $218 |
| Novo Nordisk | 20 | $204 |
| Johnson & Johnson | 12 | $191 |
| Boehringer Ingelheim | 7 | $136 |
| Biosense Webster, Inc. | 4 | $122 |
| Xeris Pharmaceuticals, Inc. | 5 | $102 |
| Bayer | 5 | $90 |
| Insulet Corporation | 3 | $90 |
| UCB, Inc. | 3 | $78 |
| GSK | 5 | $77 |
| Radius Health, Inc. | 3 | $75 |
| Tandem Diabetes Care, Inc. | 2 | $75 |
| Novartis | 4 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Rhythm Pharmaceuticals, Inc. | 3 | $62 |
| AstraZeneca(2 entities) | 3 | $56 |
| Cequr Corporation | 1 | $55 |
| Amneal Pharmaceuticals LLC | 3 | $54 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Recordati_rare_diseases_inc. | 2 | $36 |
| Genentech USA, Inc. | 2 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$421
- Prolia$120
How this compares
$4,729 in reported general payments places this provider in the 60th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $46,956 |
| TrulicityDulaglutide | 18 | $35,093 |
| JardianceEmpagliflozin | 21 | $31,881 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $26,947 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $7,276 |
| SynthroidLevothyroxine Sodium | 63 | $6,283 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $5,142 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,874 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $2,129 |
| Levothyroxine Sodium | 169 | $1,574 |
| Metformin Hcl | 32 | $1,189 |
| Metformin Hcl ErMetformin Hcl | 47 | $731 |
| Ultra-Fine Nano Pen NeedlePen Needle, Diabetic | 11 | $726 |
| Liothyronine Sodium | 19 | $415 |
| Rosuvastatin Calcium | 26 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $204 | $46,95643 claims |
| Lilly USA, LLCTrulicity | $478 | $35,09318 claims |
| Boehringer IngelheimJardiance | $136 | $31,88121 claims |
| AbbVieSynthroid | $477 | $6,28363 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $54 | $1,647182 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Scottsdale
- Amir HarariScottsdale$361K
- Kristina BlohmScottsdale$220K
- Andrea FerencziScottsdale$132K
- Sreedevi ReddyScottsdale$28K
- Grace Zlaket MattaScottsdale$17K
- Heather SaranScottsdale$14K
- Chandana MishraScottsdale$11K
- Vincent LiouScottsdale$10K
- Kimberlee BrontsemaScottsdale$9K
- Dena HaddadScottsdale$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.